The FDA's top regulator of cancer drugs played a key role in the rejection of a skin cancer therapy from Replimune Group, ...

Risk assessment for potential mutagenic side-products is still required by regulatory bodies, despite lack of evidence they ...

Evaluating electrocardiogram (ECG) traces using a new deep-learning model known as EchoNext looks set to save lives by flagging patients at high risk of structural heart disease (SHD) who might ...